These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients. Vaghasiya RP; DeVita MV; Michelis MF Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553 [TBL] [Abstract][Full Text] [Related]
9. Hyponatremia in heart failure: the role of arginine vasopressin and diuretics. Rosner MH Cardiovasc Drugs Ther; 2009 Aug; 23(4):307-15. PubMed ID: 19554441 [TBL] [Abstract][Full Text] [Related]
10. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Onogawa T; Sakamoto Y; Nakamura S; Nakayama S; Fujiki H; Yamamura Y Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S67-76. PubMed ID: 22120095 [TBL] [Abstract][Full Text] [Related]
11. Vasopressin receptor antagonists: mechanisms of action and potential effects in heart failure. Goldsmith SR Cleve Clin J Med; 2006 Jun; 73 Suppl 2():S20-3; discussion S30-3. PubMed ID: 16786909 [TBL] [Abstract][Full Text] [Related]
12. [Vasopressin antagonists in treatment of hyponatremia]. Olszewski W; Głuszek J Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383 [TBL] [Abstract][Full Text] [Related]
13. A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Wada K; Matsukawa U; Fujimori A; Arai Y; Sudoh K; Sasamata M; Miyata K Biol Pharm Bull; 2007 Jan; 30(1):91-5. PubMed ID: 17202666 [TBL] [Abstract][Full Text] [Related]
14. BSC1 inhibition complements effects of vasopressin V2 receptor antagonist on hyponatremia in SIADH rats. Kazama I; Hatano R; Michimata M; Suzuki K; Arata T; Suzuki M; Miyama N; Sato A; Satomi S; Ejima Y; Sasaki S; Matsubara M Kidney Int; 2005 May; 67(5):1855-67. PubMed ID: 15840033 [TBL] [Abstract][Full Text] [Related]
15. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Goldsmith SR Am J Cardiol; 2005 May; 95(9A):14B-23B. PubMed ID: 15847853 [TBL] [Abstract][Full Text] [Related]
16. In right or biventricular chronic heart failure addition of thiazides to loop diuretics to achieve a sequential blockade of the nephron is associated with increased risk of dilutional hyponatremia: results of a case-control study. De Vecchis R; Ariano C; Esposito C; Giasi A; Cioppa C; Cantatrione S Minerva Cardioangiol; 2012 Oct; 60(5):517-29. PubMed ID: 23018431 [TBL] [Abstract][Full Text] [Related]
17. Vasopressin antagonists: role in the management of hyponatremia. Yeates KE; Morton AR Am J Nephrol; 2006; 26(4):348-55. PubMed ID: 16837788 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of vasopressin receptor antagonists. Ali F; Guglin M; Vaitkevicius P; Ghali JK Drugs; 2007; 67(6):847-58. PubMed ID: 17428103 [TBL] [Abstract][Full Text] [Related]
19. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure. Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782 [TBL] [Abstract][Full Text] [Related]
20. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]